Business Wire

Adtran Networks SE reports second quarter 2023 results

8.8.2023 06:00:00 EEST | Business Wire | Press release

Share

Adtran Networks SE (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported financial results for the second quarter 2023 ended on June 30, 2023. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).

Q2 2023 financial summary1

(in thousands of EUR)

Q2

Q2

Change

Q1

Change

 

 

2023

2022

 

2023

 

 

 

 

Revenues

170,188

166,320

2.3%

179,358

-5.1%

 

Pro forma gross profit

60,232

54,336

10.9%

58,371

3.2%

 

in % of revenues

35.4%

32.7%

2.7pp

32.5%

2.8pp

 

Pro forma EBIT

12,092

6,435

87.9%

9,730

24.3%

 

in % of revenues

7.1%

3.9%

3.2pp

5.4%

1.7pp

 

Operating income2

8,033

4,655

72.6%

6,227

29.0%

 

Net income

3,288

7,291

-54.9%

3,627

-9.3%

 

 

 

(in thousands of EUR)

Jun. 30

2023

Jun. 30

2022

Change

Mar. 31

2023

Change

 

Cash and cash equivalents

48,595

63,187

-23,1%

67,241

-27.7%

 

Net cash (+) / Net debt (-)3

-33,457

-946

-3,436.7%

-24,296

-37.7%

 

1 Potential difference due to rounding

2 Q2 2023 including EUR 1.7 million, Q1 2023 including EUR 1.6 million and Q2 2022 including EUR 0.4 million extraordinary expenses

3 Q2 2023 including EUR 53.0 million and Q1 2023 Including EUR 62.0 million financial liabilities to Adtran Holdings, Inc.

Q2 2023 IFRS financial results
Revenue in Q2 2023 was down 5.1% to EUR 170.2 million from EUR 179.4 million in Q1 2023 and was up 2.3% compared to EUR 166.3 million in Q2 2022. The US Dollar depreciation negatively impacted both year-over-year and quarter-over-quarter revenue. The decrease compared to the previous quarter was mainly due to a softening in demand compared to a strong Q1 2023.

Pro forma gross profit in Q2 2023 was up 3.2% to EUR 60.2 million (35.4% of revenues) from EUR 58.4 million (32.5% of revenues) in Q1 2023 and increased by 10.9% from EUR 54.3 million (32.7% of revenues) in the year-ago quarter. The margin increase is due to lower procurement costs related to the recovery of supply bottlenecks and the US Dollar depreciation.

Pro forma EBIT in Q2 2023 was EUR 12.1 million (7.1% of revenues), up 24.3% from EUR 9.7 million (5.4% of revenues) in Q1 2023. Compared to the year-ago quarter, pro forma operating income increased by 87.9% from EUR 6.4 million (3.9% of revenues). The increase in pro forma EBIT is mainly due to the improvement in gross margin.

Operating income increased by 29.0% from EUR 6.2 million in Q1 2023 to EUR 8.0 million in Q2 2023 and increased by 72.6% compared to EUR 4.7 million in Q2 2022.

Net income was EUR 3.3 million in Q2 2023, down 9.3% compared to EUR 3.6 million in Q1 2023 and down 54.9% compared to EUR 7.3 million in Q2 2022. The decrease in net income was due to higher tax charges in Q2 2023.

The company’s cash and cash equivalents decreased by EUR 18.6 million to EUR 48.6 million compared to EUR 67.2 million at the end of Q1 2023 and decreased by EUR 14.6m million compared to EUR 63.2 million in Q2 2022.

The company’s net debt increased by EUR 9.2 million from EUR 24.3 million in Q1 2023 to EUR 33.5 million in Q2 2023 and increased by EUR 32.5 million compared to EUR 0.9 million in Q2 2022.

Management commentary
“Our Q2 2023 results were in line with our expectations. We anticipate the second half of 2023 will continue to present challenges due to customers optimizing inventory and the macro-economic environment,” said Tom Stanton, CEO of Adtran Networks SE. “Nevertheless, we continue to believe that we are in the early stage of an unprecedented investment cycle and Adtran Networks is well positioned to be one of the largest beneficiaries.”

The company will publish its financial results for Q3 2023 on November 7, 2023.

The complete half-year report 2023 (January – June) is available as a PDF: https://www.adva.com/en/about-us/investors/financial-results/financial-statements

Forward-looking statements
The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of Adtran Networks. Adtran Networks is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of Adtran Networks or the market in the shares of Adtran Networks.

Use of pro forma financial information
Adtran Networks SE provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of Adtran Networks operating results from one financial period to another. Adtran Networks believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, non-recurring expenses relating to M&A restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.

About Adtran Networks SE
Adtran Networks SE is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by
Adtran Networks SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press
Gareth Spence
+44 1904 699 358
public-relations@adva.com

For investors
Steven Williams
+49 89 890 665 918
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye